Browse studies

Find your next paid study

27,293 recruiting studies available now

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 year…

Moderate-to-Severe Atopic Dermatitis

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Nektar TherapeuticsNCT07690371

Phase 2

Efficacy of Molecularly Driven, Time-limited Treatment With Ropeg-interferon in Newly Diagnosed Patients With JAK2- Mutant Polycythemia Vera - a Multicenter, Single-arm, Phase II Study

The researchers are doing this study to find out whether it is practical (feasible) to stop treatment with ropeg-interferon (ropeg-INF) for some people with po…

Polycythemia Vera (PV)JAK2 Mutation

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07886801

Phase 1

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

This is a ﬁrst in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efﬁcacy of CER-1236 in patients with relapsed/refrac…

AMLAcute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Estimated

~$150 – $4,200

Actual pay is set by the research site.

CERo Therapeutics Holdings, Inc.NCT06834282

The FLOW Registry: Functional and Longitudinal Outcomes With Waterjet Ablation

The purpose of this study is to create a database and prospective registry for data collection on patients with benign prostatic hyperplasia undergoing Aquabla…

Benign Prostatic Hyperplasia (BPH)

Estimated

~$10 – $750

Actual pay is set by the research site.

University of ChicagoNCT07430423

Phase 1

A Randomized, Double-Masked, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ETHY-001

The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and partici…

Thyroid Eye Disease (TED)Graves' DiseaseEye Diseases, Hereditary+11 more

Estimated

~$500 – $10,500

Actual pay is set by the research site.

Ethyreal Bio, Inc.NCT07885605

Phase 1

A Multicenter, Sham-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Responses Following Stereotactic Intracranial Implantation of DSP-1083 Into Subjects With Parkinson's Disease

The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female p…

Parkinson's Disease

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Sumitomo Pharma America, Inc.NCT06753331

Phase 2

A Phase 2a Randomized, Double-Blind Study to Evaluate the Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab in Patients With Amyotrophic Lateral Sclerosis (ALS)

The goal of this clinical trial is to learn whether a nasal spray medicine called foralumab is safe and easy to tolerate in adults with amyotrophic lateral scl…

ALS (Amyotrophic Lateral Sclerosis)ALS - Amyotrophic Lateral SclerosisALS

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Tiziana Life Sciences LTDNCT07688239

Phase 1

Clinical Trial of D2C7-IT + 2141-V11 Combination Immunotherapy Administered Via Convection Enhanced Delivery in Non-enhancing Tumor Post-resection of Recurrent Glioblastoma, Followed by Cervical Perilymphatic Subcutaneous Injections of 2141-V11

The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with …

Recurrent Glioblastoma IDH Wildtype

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Darell BignerNCT06455605

Phase 3

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Participants With Chronic Painful Lumbosacral Radiculopathy

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for wh…

Lumbosacral Radiculopathy

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Vertanical GmbHNCT06956014

Phase 4

COMFORT Trial: Complex Obstetric Management With Focused Regional Transversus Abdominis Plane Block

To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents…

Complex Obstetric SurgeryPerioperative Pain ManagementCesarean Delivery+1 more

Estimated

~$25 – $1,000

Actual pay is set by the research site.

University of TennesseeNCT06925152

Observational

Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter

The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to…

AneurysmAneurysm, Intracranial

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Stryker NeurovascularNCT06872684

Phase 1

A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics

The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendatio…

Hepatic Impairment

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07872033